Dizal Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dizal Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Dizal Pharmaceuticals: 15 sponsored US clinical trials, 2 recruiting.
Dizal Pharmaceuticals sponsors 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 10 completed. 1 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 3 trials.
Top-decile sponsor footprint
Dizal Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
NCT06905197
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05824585
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022
DZD9008 PK Study in Hepatic Impairment Subjects
NCT06084104
Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine
NCT05486949
Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine
NCT05418582
Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects
NCT05159895
A Study of DZD2269 in Healthy Adult Participants
NCT04932005
Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants
NCT04909242
Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
NCT04634344
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
NCT04509596
Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers
NCT04225208
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
NCT04105010
A Study of AZD4205 in Healthy Adult Subjects
NCT03728023
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Dizal Pharmaceuticals pipeline
2 recruiting of 15 indexed (13% open); 10 completed (67%).
Phase mix: 1 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Non-Small Cell Lung Cancer (3 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dizal Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 15 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Dizal Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Edgewise Therapeutics · 13% recruiting · 15 trials
- EpicentRx · 13% recruiting · 15 trials
- European Organisation for Research and Treatment of Cancer - EORTC · 13% recruiting · 15 trials
Related
What to do with this Dizal Pharmaceuticals page
15 registered trials is a research-attention snapshot, not an endorsement of Dizal Pharmaceuticals or any single study.
- 2 of Dizal Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Small Cell Lung Cancer is the condition Dizal Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Dizal Pharmaceuticals pipeline card: 15 registered trials from official public datasets.Report a data error.